| 9.72 -0.1 (-1.02%) | 04-25 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.61 | 1-year : | 18.65 |
| Resists | First : | 13.36 | Second : | 15.97 |
| Pivot price | 12.11 |
|||
| Supports | First : | 9.15 | Second : | 7.61 |
| MAs | MA(5) : | 9.83 |
MA(20) : | 12.72 |
| MA(100) : | 12.15 |
MA(250) : | 14.4 |
|
| MACD | MACD : | -0.9 |
Signal : | -0.4 |
| %K %D | K(14,3) : | 12.1 |
D(3) : | 10.8 |
| RSI | RSI(14): 34.5 |
|||
| 52-week | High : | 27.03 | Low : | 8.25 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ DTIL ] has closed above bottom band by 18.2%. Bollinger Bands are 84% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 4 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 10.12 - 10.18 | 10.18 - 10.24 |
| Low: | 9.5 - 9.56 | 9.56 - 9.63 |
| Close: | 9.6 - 9.71 | 9.71 - 9.83 |
Precision BioSciences, Inc., a clinical stage gene editing company, develops in vivo gene editing and ex vivo allogeneic CAR T therapies in the United States. It offers ARCUS, a genome editing platform to cure genetic disorders. The company also provides Ex vivo Allogeneic CAR T Immunotherapy, a form of immunotherapy in which T cell, a specific type of immune cell is genetically engineered to recognize and kill cancer cells; PBCAR0191, which is in Phase 1/2a clinical trial in adult patients with R/R NHL or R/R B-cell precursor acute lymphoblastic leukemia, or B-ALL; PBCAR19B, an anti-CD19 CAR T candidate built on the stealth cell platform utilizing a single-step gene edit to minimize the risk of chromosome abnormalities; and PBCAR269A, an investigational allogeneic CAR T immunotherapy targeting BCMA for the treatment of R/R multiple myeloma. The company has development and commercial license agreement with Les Laboratoires Servier to develop allogeneic chimeric antigen receptor T cell therapies for antigen targets, hematological cancer targets beyond CD19, and solid tumor targets; Tiziana Life Sciences to evaluate foralumab, a fully human anti-CD3 monoclonal antibody as a lymphodepleting agent for the potential treatment of cancers; and iECURE, Inc. to develop ARCUS-based gene editing therapies. Precision BioSciences, Inc. was incorporated in 2006 and is headquartered in Durham, North Carolina.
Mon, 22 Apr 2024
Precision BioSciences (DTIL) Reports Q2 Loss, Tops Revenue Estimates - Yahoo Canada Shine On
Tue, 16 Apr 2024
Eli Lilly subsidiary, Precision Biosciences end gene therapy collaboration (NASDAQ:DTIL) - Seeking Alpha
Thu, 11 Apr 2024
Precision BioSciences (DTIL) Now Trades Above Golden Cross: Time to Buy? - Zacks Investment Research
Wed, 27 Mar 2024
Precision BioSciences: Q4 Earnings Snapshot - WRAL News
Wed, 20 Mar 2024
Precision BioSciences stock target raised to $30 on gene editing prospects - Investing.com
Wed, 20 Mar 2024
Precision BioSciences to Report Fourth Quarter and Fiscal Year 2023 Results on March 27, 2024 - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Neutral |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 7 (M) |
| Shares Float | 5 (M) |
| Held by Insiders | 8.4 (%) |
| Held by Institutions | 39.7 (%) |
| Shares Short | 289 (K) |
| Shares Short P.Month | 49 (K) |
| EPS | -332.12 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 4.53 |
| Profit Margin | -125.9 % |
| Operating Margin | -211.6 % |
| Return on Assets (ttm) | -13.8 % |
| Return on Equity (ttm) | -107.3 % |
| Qtrly Rev. Growth | -33.6 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 7.04 |
| EBITDA (p.s.) | -5.34 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -84 (M) |
| Levered Free Cash Flow | -50 (M) |
| PE Ratio | -0.03 |
| PEG Ratio | 0 |
| Price to Book value | 2.14 |
| Price to Sales | 1.38 |
| Price to Cash Flow | -0.8 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|